Ribavirin Teva Pharma B.V.

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Рибавирин

Available from:

Teva B.V.

ATC code:

J05AP01

INN (International Name):

ribavirin

Therapeutic group:

Антивирусни средства за системно приложение

Therapeutic area:

Хепатит C, хроничен

Therapeutic indications:

Ribavirin Teva Pharma B. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis C (CHC) in adults (see sections 4. 2, 4. 4 и 5. Ribavirin Teva Pharma B. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) notpreviously treated and without liver decompensation (see sections 4. 2, 4. 4 и 5.

Product summary:

Revision: 14

Authorization status:

Отменено

Authorization date:

2009-07-01

Patient Information leaflet

                                75
Б. ЛИСТОВКА
Лекарствен продукт с невалидно
разрешение за употреба
76
ЛИСТОВКА: ИНФОРМАЦИЯ ЗА ПОТРЕБИТЕЛЯ
РИБАВИРИН TEVA PHARMA B.V. 200 MG ФИЛМИРАНИ
ТАБЛЕТКИ
рибавирин (
_ribavirin_
)
ПРОЧЕТЕТЕ ВНИМАТЕЛНО ЦЯЛАТА ЛИСТОВКА
ПРЕДИ ДА ЗАПОЧНЕТЕ ДА ПРИЕМАТЕ ТОВА
ЛЕКАРСТВО,
ТЪЙ КАТО ТЯ СЪДЪРЖА ВАЖНА ЗА ВАС
ИНФОРМАЦИЯ.
-
Запазете тази листовка. Може да се
наложи да я прочетете отново.
-
Ако имате някакви допълнителни
въпроси, попитайте Вашия лекар,
фармацевт или
медицинска сестра.
-
Това лекарство е предписано лично на
Вас. Не го преотстъпвайте на други
хора. То може
да им навреди, независимо от това, че
техните симптоми са същите като
Вашите.
-
Ако получите някакви нежелани
лекарствени реакции, уведомете Вашия
лекар,
фармацевт или медицинска сестра. Това
включва и всички възможни нежелани
реакции,
неописани в тази листовка. Вижте точка
4.
КАКВО СЪДЪРЖА ТАЗИ ЛИСТОВКА
:
1.
Какво представлява Рибавирин Teva Pharma
B.V. и за какво се използва
2.
Какво трябва да знаете, преди да
приемете Рибавирин Teva Pharma B.V.
3.
Как да приемате Рибавирин Teva Pharma B.V.
4.
Възможни нежелани реакции
5.
Как да съхранявате Рибавирин Teva Pharma B.V.
6.
Съдържание на опаковката и
допъл
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
Лекарствен продукт с невалидно
разрешение за употреба
2
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Рибавирин Teva Pharma B.V. 200 mg филмирани
таблетки
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Всяка таблетка Рибавирин Teva Pharma B.V.
съдържа 200 mg рибавирин
_(ribavirin)._
За пълния списък на помощните
вещества, вижте точка 6.1.
3.
ЛЕКАРСТВЕНА ФОРМА
Филмирана таблетка.
Светло розова до розова филмирана
таблетка (с принтиран надпис “93” от
едната страна и
“7232” от другата).
4.
КЛИНИЧНИ ДАННИ
4.1
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
Рибавирин Teva Pharma B.V., в комбинация с
други лекарствени продукти, е показан
за лечение
на хроничен хепатит С (chronic hepatitis C, СНС)
при възрастни (вж. точки 4.2, 4.4 и 5.1).
Рибавирин Teva Pharma B.V., в комбинация с
други лекарствени продукти, е показан
за лечение
на хроничен хепатит С (СНС) при
педиатрични пациенти (деца на възраст
3 години и по-
големи и юноши), без предходно лечение
и без чернодробна декомпенсация (вж.
точки 4.2, 4.4
и 5.1).
4.2
ДОЗИРОВКА И НАЧИН НА ПРИЛОЖЕНИЕ
Лечението трябва да бъде започнато и
да се проследява от лекар с опит в
лечението на
хроничен хепатит С.
Дозировка
Рибавирин Teva Pharma B.V. трябва да се
прил
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 09-07-2021
Public Assessment Report Public Assessment Report Spanish 09-07-2021
Patient Information leaflet Patient Information leaflet Czech 09-07-2021
Public Assessment Report Public Assessment Report Czech 09-07-2021
Patient Information leaflet Patient Information leaflet Danish 09-07-2021
Public Assessment Report Public Assessment Report Danish 09-07-2021
Patient Information leaflet Patient Information leaflet German 09-07-2021
Public Assessment Report Public Assessment Report German 09-07-2021
Patient Information leaflet Patient Information leaflet Estonian 09-07-2021
Public Assessment Report Public Assessment Report Estonian 09-07-2021
Patient Information leaflet Patient Information leaflet Greek 09-07-2021
Public Assessment Report Public Assessment Report Greek 09-07-2021
Patient Information leaflet Patient Information leaflet English 09-07-2021
Public Assessment Report Public Assessment Report English 09-07-2021
Patient Information leaflet Patient Information leaflet French 09-07-2021
Public Assessment Report Public Assessment Report French 09-07-2021
Patient Information leaflet Patient Information leaflet Italian 09-07-2021
Public Assessment Report Public Assessment Report Italian 09-07-2021
Patient Information leaflet Patient Information leaflet Latvian 09-07-2021
Public Assessment Report Public Assessment Report Latvian 09-07-2021
Patient Information leaflet Patient Information leaflet Lithuanian 09-07-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 09-07-2021
Public Assessment Report Public Assessment Report Lithuanian 09-07-2021
Patient Information leaflet Patient Information leaflet Hungarian 09-07-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 09-07-2021
Public Assessment Report Public Assessment Report Hungarian 09-07-2021
Patient Information leaflet Patient Information leaflet Maltese 09-07-2021
Public Assessment Report Public Assessment Report Maltese 09-07-2021
Patient Information leaflet Patient Information leaflet Dutch 09-07-2021
Public Assessment Report Public Assessment Report Dutch 09-07-2021
Patient Information leaflet Patient Information leaflet Polish 09-07-2021
Public Assessment Report Public Assessment Report Polish 09-07-2021
Patient Information leaflet Patient Information leaflet Portuguese 09-07-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 09-07-2021
Public Assessment Report Public Assessment Report Portuguese 09-07-2021
Patient Information leaflet Patient Information leaflet Romanian 09-07-2021
Public Assessment Report Public Assessment Report Romanian 09-07-2021
Patient Information leaflet Patient Information leaflet Slovak 09-07-2021
Public Assessment Report Public Assessment Report Slovak 09-07-2021
Patient Information leaflet Patient Information leaflet Slovenian 09-07-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 09-07-2021
Public Assessment Report Public Assessment Report Slovenian 09-07-2021
Patient Information leaflet Patient Information leaflet Finnish 09-07-2021
Public Assessment Report Public Assessment Report Finnish 09-07-2021
Patient Information leaflet Patient Information leaflet Swedish 09-07-2021
Public Assessment Report Public Assessment Report Swedish 09-07-2021
Patient Information leaflet Patient Information leaflet Norwegian 09-07-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 09-07-2021
Patient Information leaflet Patient Information leaflet Icelandic 09-07-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 09-07-2021
Patient Information leaflet Patient Information leaflet Croatian 09-07-2021
Public Assessment Report Public Assessment Report Croatian 09-07-2021

Search alerts related to this product